Cstone Pharmaceuticals Sustainability Profile
Cstone Pharmaceuticals, also known as Cstone Pharma, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2015, the company has rapidly established itself in the oncology sector, focusing on the development of innovative therapies for cancer treatment. With a strong presence in both domestic and international markets, Cstone operates in key regions including Asia and North America. The company’s core offerings include a range of targeted therapies and immuno-oncology products, distinguished by their unique mechanisms of action and commitment to improving patient outcomes. Cstone Pharmaceuticals has achieved significant milestones, including successful clinical trials and strategic partnerships, positioning itself as a notable player in the global biopharmaceutical landscape. With a dedication to advancing cancer care, Cstone continues to drive innovation and expand its portfolio of life-changing therapies.
DitchCarbon Score
How does Cstone Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cstone Pharmaceuticals's score of 24 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cstone Pharmaceuticals's reported carbon emissions
In 2024, Cstone Pharmaceuticals reported total carbon emissions of approximately 379,040 kg CO2e, all of which were classified under Scope 2 emissions. This represents a decrease from the previous year's total of approximately 446,630 kg CO2e in 2023, also entirely from Scope 2. The company has not disclosed any Scope 1 or Scope 3 emissions data for these years. Cstone Pharmaceuticals has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in the Science Based Targets initiative (SBTi). The absence of documented reduction targets suggests a need for further development in their climate strategy. Overall, Cstone Pharmaceuticals is actively monitoring its carbon footprint, particularly in Scope 2 emissions, but lacks comprehensive climate commitments or reduction initiatives at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - |
| Scope 2 | 591,590 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is Cstone Pharmaceuticals's Industry?
How Carbon Intensive is Cstone Pharmaceuticals's Location?
Cstone Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cstone Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.